Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07NGJ
|
||||
| Former ID |
DIB009251
|
||||
| Drug Name |
S-23906-1
|
||||
| Synonyms |
S-23906; Rac-cis-1,2-Bis(acetoxy)-6-methoxy-3,3,14-trimethyl-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridin-7-one
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Discontinued in Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Binder | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016219) | ||||
| REF 2 | Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. Mol Pharmacol. 2001 Dec;60(6):1383-91. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.